Clinical Trial Search

Primary: Baseline-adjusted Area Under Effect Curve (AUEC) for LDL-C for Evolocumab and Alirocumab — -380; -754; -866; -1832 mg/dL*day

Primary: Maximum Observed Concentration (Cmax) of Cabotegravir (CAB) Following Single IM Injection — 3.38 Microgram per milliliter (ug/mL)

Primary: Area Under Effect Curve (AUEC) for Neopterin for Interferon Beta-1a and Peginterferon Beta-1a — 7.82; 9.61; 11.08; 11.52 ng*day/mL

Primary: Area Under Effect Curve (AUEC) for Eosinophils for Mepolizumab and Reslizumab — -1804; -195; -1456; -1428 Percentage change from baseline * day

Primary: Maximum Observed Plasma Concentration (Cmax) of Sotorasib — 5080; 4850; 7250 ng/mL

Primary: Number of Participants Experiencing Adverse Events When Treated With S48168 (ARM210) — 0; 0; 0; 0 Participants

Primary: Ketoprofen Plasma PK Parameters: Cmax — 3.61; 3.40 μg/mL — p=0.1455

Primary: Number of Participants With Adverse Events (AEs) — 6 Participants

Primary: The Percentage of Participants With Adverse Events (AEs), Coded to the Medical Dictionary for Regulatory Activities - System Organ Class Eye Disorders, as Determined by…

Primary: Percentage of Participants With Local Reactions Within 7 Days After Administration of Study Intervention — 0.0; 0.0; 0.0; 2.3 Percentage of participants

Primary: Amount of Nicotine (mL of Smoke/Vapor) Inhaled — 0; 489.0; 1814.0; 1401.0 Volume in mL

Primary: PK Outcome: Cmax of ONO-4538 — 26.0; 64.3; 242.0 µg/mL

Primary: Number of Treatment-Emergent Adverse Events [Safety and Tolerability] — 0; 1; 1; 1 Participants

Primary: Maximum Observed Serum Concentration (Cmax) of Romosozumab — 2.64; 1.74; 13.8; 10.3 μg/mL

Primary: Phase Ia: Number of Patients With DLTs Observed in the First Cycle — 0; 0; 0; 0 Participants